Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis
Facial Nerve Injuries, Facial Paresis Associated With Facial Nerve Dysfunction, Facial Asymmetry
About this trial
This is an interventional treatment trial for Facial Nerve Injuries focused on measuring Facial paralysis, Facial synkinesis, Botulinum toxin
Eligibility Criteria
Inclusion Criteria:
- Facial synkinesis
Exclusion Criteria:
- Previous complication from botulinum toxin neuromodulator injection
- Inability to understand or complete the SAQ survey
- Inability to participate in follow-up
- Pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
OnabotulinumtoxinA Injectable Product
AbobotulinumtoxinA Injectable Product
Incobotulinumtoxin A Injectable Product
onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.